85 related articles for article (PubMed ID: 8444677)
21. Tentative minimum inhibitory concentration and zone diameter breakpoints for moxifloxacin using BSAC criteria.
Andrews JM; Ashby JP; Jevons GM; Wise R
J Antimicrob Chemother; 1999 Dec; 44(6):819-22. PubMed ID: 10590284
[TBL] [Abstract][Full Text] [Related]
22. Effect of RO 23-9424, cefotaxime and fleroxacin on functions of human polymorphonuclear cells and cytokine production by human monocytes.
Matera G; Berlinghieri MC; Foti F; Barreca GS; Focà A
J Antimicrob Chemother; 1996 Nov; 38(5):799-807. PubMed ID: 8961049
[TBL] [Abstract][Full Text] [Related]
23. In vitro activity of Ro 23-9424, ceftazidime, and eight other newer beta-lactams against 100 gram-positive blood culture isolates.
Jones RN; Barry AL
Diagn Microbiol Infect Dis; 1989; 12(2):143-7. PubMed ID: 2666014
[TBL] [Abstract][Full Text] [Related]
24. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
Beskid G; Prosser BL
Am J Med; 1993 Mar; 94(3A):2S-8S. PubMed ID: 8383919
[TBL] [Abstract][Full Text] [Related]
25. Comparative in vitro activity of Ro 09-1428, a novel cephalosporin with a catechol moiety.
Qadri SM; Ayub A; Ueno Y; Saldin H
Clin Ther; 1992; 14(4):562-9. PubMed ID: 1525790
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of Ro 13-9904, a new beta-lactamase-stable cephalosporin.
Verbist L; Verhaegen J
Antimicrob Agents Chemother; 1981 Feb; 19(2):222-5. PubMed ID: 6289726
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of Ro 24-6392, a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.
Jones RN
Eur J Clin Microbiol Infect Dis; 1990 Jun; 9(6):435-8. PubMed ID: 2387298
[TBL] [Abstract][Full Text] [Related]
28. Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolones.
Fuchs PC; Barry AL; Brown SD
Diagn Microbiol Infect Dis; 1996 Sep; 26(1):23-7. PubMed ID: 8950525
[TBL] [Abstract][Full Text] [Related]
29. Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing.
Fuchs PC; Barry AL; Thornsberry C; Jones RN; Gavan TL; Gerlach EH; Sommers HM
Antimicrob Agents Chemother; 1980 Jul; 18(1):88-93. PubMed ID: 6251750
[TBL] [Abstract][Full Text] [Related]
30. beta-Lactamase hydrolysis of cephalosporin 3'-quinolone esters, carbamates, and tertiary amines.
Georgopapadakou NH; McCaffrey C
Antimicrob Agents Chemother; 1994 May; 38(5):959-62. PubMed ID: 8067776
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals.
Christenson JG; Chan KK; Cleeland R; Dix-Holzknecht B; Farrish HH; Patel IH; Specian A
Antimicrob Agents Chemother; 1990 Oct; 34(10):1895-900. PubMed ID: 2127171
[TBL] [Abstract][Full Text] [Related]
32. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.
King A; Bethune L; Phillips I
J Antimicrob Chemother; 1991 Nov; 28(5):719-25. PubMed ID: 1663930
[TBL] [Abstract][Full Text] [Related]
33. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
Cormican MG; Jones RN
J Antimicrob Chemother; 1995 Aug; 36(2):431-4. PubMed ID: 8522474
[TBL] [Abstract][Full Text] [Related]
34. [Clinical laboratory approach for estimating effective administrative dosage of cefmenoxime. Observation on the MICS and cefmenoxime disc susceptibility test].
Uete T; Matsuo K
Jpn J Antibiot; 1984 May; 37(5):791-801. PubMed ID: 6090721
[TBL] [Abstract][Full Text] [Related]
35. In-vitro activity of four new fluoroquinolones.
García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of lomefloxacin, a difluorinated quinolone, compared with other antimicrobials.
Qadri SM; Lee GC; Ellis ME
Chemotherapy; 1991; 37(3):166-74. PubMed ID: 1889304
[TBL] [Abstract][Full Text] [Related]
37. Antimicrobial activity of Ro 19-5247 (T-2525), a new oral cephalosporin, tested against 7,745 recent clinical isolates.
Jones RN; Fuchs PC; Barry AL; Ayers LW; Gerlach EH; Gavan TL
Diagn Microbiol Infect Dis; 1987 Mar; 6(3):193-8. PubMed ID: 3568594
[TBL] [Abstract][Full Text] [Related]
38. Antimicrobial susceptibility tests with cefotaxime and correlation with clinical bacteriologic response.
Thornsberry C; Jones RN; Barry AL; Fuchs PC
Rev Infect Dis; 1982; 4 Suppl():S316-24. PubMed ID: 6294780
[TBL] [Abstract][Full Text] [Related]
39. Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review.
Jones RN
Diagn Microbiol Infect Dis; 1995; 22(1-2):19-33. PubMed ID: 7587039
[TBL] [Abstract][Full Text] [Related]
40. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
Barry AL; Fuchs PC
J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
